Loading clinical trials...
Loading clinical trials...
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT06326905 · Quality of Life, Depression, and more
NCT07157397 · End Stage Renal Disease (ESRD), End Stage Kidney Disease (ESRD), and more
NCT07020832 · Delayed Graft Function, End Stage Renal Disease, and more
NCT07153939 · Chronic Kidney Disease, Hemodialysis Access, and more
NCT07146854 · End Stage Renal Disease (ESRD)
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions